Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | UH15-38 is a powerful RIPK3 inhibitor, exhibiting an IC50 of 20 nM. It effectively blocks necroptosis triggered by the influenza A virus (IAV) and mitigates lung damage induced by IAV. |
Targets&IC50 | RIPK3:20 nM |
In vitro | UH15-38, administered at 30 mg/kg intraperitoneally (i.p.) daily for 4 days, effectively mitigates lung damage induced by IAV[1]. In the study with a C57Bl/6 mouse model challenged with a lethal dose of PR8 (6,000 × EID50) [1], the treatment commenced 24 hours post-infection and resulted in a significant reduction of pMLKL+ necroptotic cells, attenuated diffuse alveolar damage, and diminished hyaline membrane formation. Additionally, UH15-38 lowered the extent of fibrotic lung injury and reduced levels of pro-fibrotic mediators, including IL-1β, IL-6, IL-18, IL-17, and CCL5. |
In vivo | UH15-38 (0-1000 nM; 12 h) reduces TCZ-induced pMLKL expression in a dose-dependent manner [1]. Additionally, UH15-38 (0-1000 nM) safeguards type I alveolar epithelial cells from typical TNF-induced necroptosis and prevents necroptosis induced by IAV [1]. |
Molecular Weight | 441.52 |
Formula | C26H27N5O2 |
Cas No. | 2540881-21-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.